Transplantation medium
Patent Information
- Application Number
- JP2024508236
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Filing Date
- 2024-09-13
- Publication Date
- 2024-11-22
AI Technical Summary
Current transplant media for retinal pigment epithelial cells fail to prevent cell leakage into the vitreous body and prolong retinal detachment during subretinal transplantation, leading to inadequate engraftment and increased side effects.
A transplantation medium with a viscosity of 1.5 to 4 mPa·s at a shear rate of 2 (1/s) at 25°C, containing hyaluronic acid and a pharmaceutically acceptable aqueous liquid, is used to suppress cell leakage and improve engraftment by maintaining a stable viscosity at different shear rates and pH levels, without antibacterial agents or preservatives, and optionally replacing the vitreous body with air post-transplantation.
The medium effectively reduces cell leakage and retinal detachment, allowing for efficient delivery and engraftment of retinal pigment epithelial cells to the desired area, minimizing side effects and enhancing the transplantation process.
Abstract
Description
transplant medium
[0001] The present invention relates to a transplantation medium, and in particular to a transplantation medium for subretinal transplantation of retinal pigment epithelial cells.
[0002] Retinal pigment epithelial (RPE) cells are pigment epithelial cells present in the outermost layer of the retina, and play important roles in maintaining photoreceptors, such as phagocytosis of photoreceptor outer segments and recycling of visual pigment. Age-related macular degeneration, which occurs when RPE cells become abnormal due to aging or other factors, is an eye disease that causes a decrease in central vision and blindness, and the development of an effective treatment is desired. In recent years, cell transplantation therapy to replenish and replace RPE cells has been attracting attention as a new treatment for age-related macular degeneration, and RPE cells are expected to be used as a transplant material for cell therapy. Several methods for inducing differentiation of RPE cells using human pluripotent stem cells are known (e.g., Patent Document 1).
[0003] A common method for transplanting RPE cells into the subretinal space within the eyeball is to, for example, aspirate an RPE cell suspension into the interior of a Surflow needle, insert the Surflow needle into the subretinal space within the eyeball, and then eject the RPE cells from the tip of the Surflow needle into the subretinal space (Non-Patent Documents 1 and 2). Because RPE cells must be accurately inserted into the affected retinal tissue in need of repair and engrafted, a medium suitable for RPE cell transplantation surgery has been sought.
[0004] Non-Patent Document 3 describes the screening and optimization of media for preserving RPE stem cells before transplantation, and the effects of each medium on the survival, attachment, distribution, proliferation, and differentiation ability of RPE stem cells into RPE cells were investigated. It also describes that when a 0.2% hyaluronic acid solution was used as a preservation medium for RPE stem cells, it was found to promote good distribution and proliferation of RPE stem cells, as well as the cobblestone formation characteristic of mature RPE cells and the expression of RPE cell markers after 96 hours of storage. However, Non-Patent Document 3 does not describe the effects of using it in actual transplant surgery. Furthermore, Patent Document 2 discloses a device for transplanting a subretinal implant (retinal cell graft), and describes the use of an aqueous hyaluronic acid solution for this purpose, but does not describe any specific retinal tissue or the concentration of hyaluronic acid. Furthermore, it has been reported that subretinal injection of hyaluronic acid can cause retinal detachment (Non-Patent Document 4). As described above, a medium to be used when transplanting RPE cells has not yet been established.
[0005] WO2017 / 043605 Special Publication No. 2005-517468
[0006] Schwartz SD et al. “Embryonic stem cell trials for macular degeneration: a preliminary report.” Lancet. 2012;379(9817):713-720Sugita S et al. “HLA-Matched Allogeneic iPS Cells-Derived RPE Transplantation for Macular Degeneration.” JClin Med. 2020;9(7):2217.Y. Tian et al. al., “Screening and optimization of potential injection vehicles for storage of retinal pigment epithelial stem cell before transplantation”, J Tissue Eng Regen Med. 2019;13(1): p76-86.T. Nakazawa, et al., “Tumor Necrosis Factor-α Mediates Photoreceptor Death in a Rodent Model of Retinal Detachment”, Investigative Ophthalmology & Visual Science, March 2011, Vol.52, No.3, p1384-1391
[0007] While investigating a suitable transplantation medium for RPE cell transplantation, the inventors discovered that transplantation in the form of an RPE cell suspension leads to problems such as the formation of an epiretinal membrane (ERM), which is thought to be due to cell leakage into the vitreous, and limited engraftment to only a portion of the injection site. Furthermore, they discovered the problem that increasing the viscosity to prevent cell leakage and improve engraftment leads to prolonged retinal detachment.
[0008] Therefore, an object of the present invention is to provide a medium for retinal pigment epithelial cell transplantation and a composition for transplantation that can suppress cell leakage into the vitreous body and prolonged retinal detachment when transplanted under the retina.
[0009] Therefore, after extensive investigation into transplantation media, it was found that a medium with a specific viscosity is the best medium for RPE cell transplantation.
[0010] That is, the present invention provides the following: [1] A transplantation medium for subretinal transplantation of retinal pigment epithelial cells, the transplantation medium having a viscosity of 1.5 to 4 mPa·s at a shear rate of 2 (1 / s) at 25°C, and comprising hyaluronic acid and a pharmaceutically acceptable aqueous liquid. [2] The transplantation medium according to [1], having a viscosity of 2 to 3 mPa·s at a shear rate of 2 (1 / s) at 25°C. [3] The transplantation medium according to [1] or [2], having a viscosity of 3 mPa·s or less at a shear rate of 1,000 (1 / s) at 25°C, and a viscosity difference of 0.5 to 1.5 mPa·s between a shear rate of 1 (1 / s) and a shear rate of 10 (1 / s). [4] The transplantation medium according to any of [1] to [3], having a pH of 7.0 to 7.5. [5] The transplantation medium according to any one of [1] to [4], wherein the pharmaceutically acceptable aqueous liquid is a balanced salt solution. [6] The transplantation medium according to any one of [1] to [5], wherein the transplantation medium does not contain an antibacterial agent or a preservative. [7] The transplantation medium according to any one of [1] to [6], wherein the transplantation does not contain chondroitin sulfate. [8] The transplantation medium according to any one of [1] to [7], wherein the vitreous body is air-substituted after subretinal transplantation. [9] A transplantation composition comprising retinal pigment epithelial cells for transplantation and the transplantation medium according to any one of [1] to [8].
[10] The retinal pigment epithelial cells for transplantation are 1 x 10 6 cells / mL~5×10 7
[11] The transplant composition according to [9], which is contained at a concentration of 10 ...
[0011] The transplantation medium and transplantation composition of the present invention can suppress cell leakage into the vitreous body and prolonged retinal detachment when transplanted under the retina, thereby enabling the transplanted retinal pigment epithelial cells to be efficiently engrafted in the desired area while reducing side effects.
[0012] Fig. 1 is a schematic diagram showing the procedure for administering RPE cells subretinally by the transvitreal cavity method. Fig. 2 shows an image obtained by fluorescent observation of RPE cells administered subretinally to an excised pig's eye in Example 1. Fig. 3 shows a low-magnification fluorescent immunostained image of a retina including a representative administration site in fluorescent immunostaining in Example 2. Fig. 4 shows a low-magnification fluorescent immunostained image of a retina including a representative administration site in fluorescent immunostaining in Example 2. Fig. 5 shows a high-magnification fluorescent immunostained image of a retina including a representative administration site in fluorescent immunostaining in Example 2.
[0013] 1. Definitions As used herein, the term "retinal pigment epithelial (RPE) cells" refers to epithelial cells present outside the neural retina in a living retina. Those skilled in the art can easily determine whether a cell is a retinal pigment epithelial cell, for example, by the expression of cell markers (RPE65, MITF, CRALBP, MERTK, BEST1, TTR, etc.), the presence of melanin granules (black-brown color), tight junctions between cells, and characteristic polygonal or cobblestone-like cell morphology. Whether a cell has the function of a retinal pigment epithelial cell can be easily determined by its ability to secrete cytokines such as VEGF and PEDF. In one aspect, the retinal pigment epithelial cells are RPE65-positive cells, MITF-positive cells, or RPE65-positive and MITF-positive cells.
[0014] The RPE cells to be transplanted herein are not particularly limited, but are preferably RPE cells derived from rodents, carnivores, or primates, and are particularly preferably human RPE cells. Furthermore, RPE cells derived from pluripotent stem cells (particularly iPS cells) are also preferred.
[0015] As used herein, the term "pluripotent stem cells" refers to cells that have the ability to self-renew and pluripotency, can be cultured in vitro, and have the ability (pluripotency) to differentiate into all cell lineages belonging to the three germ layers (ectoderm, mesoderm, and endoderm).
[0016] Examples of pluripotent stem cells include embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells). The pluripotent stem cells used in the present invention are mammalian pluripotent stem cells, preferably rodent, carnivorous, or primate pluripotent stem cells, and more preferably human pluripotent stem cells. Here, examples of mammals include primates such as humans and monkeys, rodents such as mice, rats, hamsters, and guinea pigs, carnivorous animals such as dogs and cats, and other animals such as pigs, cows, goats, horses, sheep, and rabbits.
[0017] Embryonic stem cells can be produced, for example, by culturing the inner cell mass present in a blastocyst-stage embryo prior to implantation on feeder cells or in a medium containing LIF. Specific methods for producing embryonic stem cells are described, for example, in WO 96 / 22362, WO 02 / 101057, US 5,843,780, US 6,200,806, and US 6,280,718. Embryonic stem cells can be obtained from designated institutions or purchased commercially. For example, human embryonic stem cells KhES-1, KhES-2, and KhES-3 are available from the Institute for Frontier Medical Sciences, Kyoto University. EB5 cells, which are mouse embryonic stem cells, are available from RIKEN, and the D3 strain is available from ATCC. Human embryonic stem cells are established from human embryos within 14 days of fertilization.
[0018] Nuclear transfer ES cells (ntES cells), which are one type of ES cell, can be established from a cloned embryo created by transplanting the nucleus of a somatic cell into an egg from which the nucleus has been removed.
[0019] "Induced pluripotent stem cells" are cells in which pluripotency has been induced by reprogramming somatic cells using known methods, etc. Specific examples include cells in which pluripotency has been induced by reprogramming somatic cells such as fibroblasts, skin cells, and peripheral blood mononuclear cells by introducing any combination of multiple reprogramming factors selected from a group of genes such as Oct3 / 4, Sox2, Klf4, Myc (c-Myc, N-Myc, L-Myc), Glis1, Nanog, Sall4, lin28, and Esrrb. Preferred combinations of reprogramming factors include (1) Oct3 / 4, Sox2, Klf4, and Myc (c-Myc or L-Myc), and (2) Oct3 / 4, Sox2, Klf4, Lin28, and L-Myc (Stem Cells, 2013;31:458-466).
[0020] In 2006, Yamanaka et al. first established induced pluripotent stem cells using mouse cells (Cell, 2006, 126(4) pp.663-676), and in 2007 they were also established using human fibroblasts (Cell, 2007, 131(5) pp.861-872; Science, 2007, 318(5858) pp.1917-1920; Nat. Biotechnol., 2008, 26(1) pp.101-106). Various improvements have been made to the methods for inducing induced pluripotent stem cells since then, and specific production methods are described, for example, in Cell. 2006 Aug 25;126(4):663-76 for mouse induced pluripotent stem cells and in Cell. 2007 Nov 30;131(5):861-72 for human induced pluripotent stem cells.
[0021] In addition to producing induced pluripotent stem cells by direct reprogramming through gene expression, induced pluripotent stem cells can also be induced from somatic cells by adding chemical compounds (Science, 2013, 341 pp. 651-654).
[0022] It is also possible to obtain established induced pluripotent stem cell lines, for example, human induced pluripotent cell lines such as 201B7 cells, 201B7-Ff cells, 253G1 cells, 253G4 cells, 1201C1 cells, 1205D1 cells, 1210B2 cells, and 1231A3 cells established at Kyoto University, which are available from Kyoto University or iPS Academia Japan Inc. Furthermore, established induced pluripotent stem cell lines, for example, Ff-I01 cells, Ff-I14 cells, and QHJI01 cells established at Kyoto University, are available from Kyoto University.
[0023] The somatic cells used in producing induced pluripotent stem cells are not particularly limited, and specific examples include fibroblasts, blood cells (e.g., peripheral blood mononuclear cells or T cells, and umbilical cord blood-derived cells), etc. Examples of fibroblasts include those derived from the dermis.
[0024] When producing induced pluripotent stem cells, if reprogramming is performed by expressing several types of reprogramming factors, the means for gene expression is not particularly limited, and any gene transfer method or direct protein injection method known to those skilled in the art can be used. Specific examples of the gene transfer method include infection methods using viral vectors (e.g., retroviral vectors, lentiviral vectors, Sendai virus vectors, adenoviral vectors, and adeno-associated viral vectors), calcium phosphate methods using plasmid vectors (e.g., plasmid vectors, episomal vectors) or RNA vectors, lipofection, retronectin, and electroporation.
[0025] When producing induced pluripotent stem cells, they can be produced in the presence or absence of feeder cells (feeder-free). When producing induced pluripotent stem cells in the presence of feeder cells, they can be produced in the presence of undifferentiated maintenance factors by known methods. The medium used when producing induced pluripotent stem cells in the absence of feeder cells is not particularly limited, and known maintenance media for embryonic stem cells and / or induced pluripotent stem cells, as well as media for establishing feeder-free induced pluripotent stem cells, can be used. Examples of media for establishing feeder-free induced pluripotent stem cells include feeder-free media such as Essential 8 medium (E8 medium), Essential 6 medium, TeSR medium, mTeSR medium, mTeSR-E8 medium, Stabilized Essential 8 medium, and StemFit (registered trademark). When producing induced pluripotent stem cells, for example, induced pluripotent stem cells can be produced by introducing four factors, Oct3 / 4, Sox2, Klf4, and Myc, into somatic cells using a Sendai virus vector in the absence of feeder cells.
[0026] The pluripotent stem cells used in the present invention are preferably induced pluripotent stem cells of rodents, carnivores or primates, and more preferably human induced pluripotent stem cells.
[0027] Pluripotent stem cells can be maintained and expanded by methods well known to those skilled in the art. However, from the viewpoint of safety in the production of transplant cells, it is preferable to maintain and expand pluripotent stem cells under serum-free conditions and in the absence of feeder cells.
[0028] Genetically modified pluripotent stem cells can be produced, for example, by using homologous recombination techniques. Examples of genes on chromosomes that can be modified include cell marker genes, histocompatibility antigen genes, and disease-related genes due to disorders of retinal pigment epithelial cells. Modification of target genes on chromosomes can be carried out using methods described in "Manipulating the Mouse Embryo, A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1994)"; "Gene Targeting, A Practical Approach, IRL Press at Oxford University Press (1993)"; "Biomanual Series 8, Gene Targeting, Generation of Mutant Mice Using ES Cells," Yodosha (1995); and the like.
[0029] Specifically, for example, genomic DNA containing a target gene to be modified (e.g., a cell marker gene, a gene for a histocompatibility antigen, or a disease-related gene) is isolated, and a target vector for homologous recombination of the target gene is prepared using the isolated genomic DNA. The prepared target vector is introduced into stem cells, and cells in which homologous recombination has occurred between the target gene and the target vector are selected, thereby producing stem cells in which a gene on a chromosome has been modified.
[0030] Methods for isolating genomic DNA containing a target gene include known methods described in, for example, Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1989) and Current Protocols in Molecular Biology, John Wiley & Sons (1987-1997). Genomic DNA containing a target gene can also be isolated using a genomic DNA library screening system (manufactured by Genome Systems) or Universal GenomeWalker Kits (manufactured by CLONTECH). Instead of genomic DNA, a polynucleotide encoding the target protein can also be used. The polynucleotide can be obtained by amplifying the corresponding polynucleotide using PCR.
[0031] Preparation of a target vector for homologous recombination of a target gene and efficient selection of homologous recombinants can be performed according to the methods described in Gene Targeting, A Practical Approach, IRL Press at Oxford University Press (1993); Biomanual Series 8, Gene Targeting, Generation of Mutant Mice Using ES Cells, Yodosha (1995); etc. Target vectors can be either replacement or insertion types. Selection methods that can be used include positive selection, promoter selection, negative selection, and polyA selection.
[0032] Methods for selecting the desired homologous recombinant from the selected cell lines include Southern hybridization and PCR for genomic DNA.
[0033] The method for producing retinal pigment epithelial cells from pluripotent stem cells is not particularly limited as long as it is a known method, and may be, for example, the method described in WO2005 / 070011, WO2006 / 080952, WO2009 / 051671, WO2011 / 063005, WO2012 / 173207, WO2015 / 053375, WO2014 / 087244, WO2014 / 121077, WO2015 / 053376, WO2015 / 068505, WO2017 / 043605, Stem Cell Reports, 2(2), 205-218 (2014), and Cell Stem Cell, 10(6), 771-785 (2012). For example, the method may be a method for producing retinal pigment epithelial cells, which is disclosed in WO2017 / 043605 and comprises the following steps (1) and (2): (1) a first step of culturing pluripotent stem cells in a medium containing an FGF receptor inhibitor and / or a MEK inhibitor for a period not exceeding 30 days (preferably 2 to 13 days or 2 to 6 days, more preferably 4 to 6 days), and (2) a second step of culturing the cells obtained in the first step in the presence of a Nodal signaling pathway inhibitor and / or a Wnt signaling pathway inhibitor to form retinal pigment epithelial cells.
[0034] The method for producing retinal pigment epithelial cells may also include the following steps (1) and (2): (1) a first step of culturing pluripotent stem cells in a medium containing an FGF receptor inhibitor and / or a MEK inhibitor for a period sufficient to induce gene expression of at least one oculogenesis transcription factor and not exceeding 30 days, and (2) a second step of culturing the cells obtained in the first step in the presence of a Nodal signaling pathway inhibitor and / or a Wnt signaling pathway inhibitor to form retinal pigment epithelial cells.
[0035] The method for producing retinal pigment epithelial cells may further comprise the following steps (1) and (2): (1) a first step of culturing pluripotent stem cells in a medium containing an FGF receptor inhibitor and / or a MEK inhibitor for a period sufficient to induce expression of at least one of PAX6, LHX2, and SIX3 genes and not exceeding 30 days, and (2) a second step of culturing the cells obtained in the first step in the presence of a Nodal signaling pathway inhibitor and / or a Wnt signaling pathway inhibitor to form retinal pigment epithelial cells.
[0036] The FGF receptor inhibitor is not particularly limited as long as it is a substance capable of suppressing signal transduction mediated by FGF, and may be any of a protein, nucleic acid, or low molecular weight compound. Here, FGFs form a family consisting of at least 22 types. Representative FGF receptors include FGFR1, FGFR2, FGFR3, and FGFR4, and the FGF receptor inhibitor is a substance that inhibits one, several, or all of these receptors. Examples of such substances include, but are not limited to, substances that act directly on FGF or FGF receptors (e.g., antibodies, aptamers, etc.), substances that suppress the expression of genes encoding FGF or FGF receptors (e.g., antisense oligonucleotides, siRNA, etc.), substances that inhibit the binding of FGF receptors to FGF (e.g., soluble FGF receptors, FGF antagonists, etc.), and substances that inhibit physiological activities resulting from signal transduction by FGF receptors (e.g., small molecular weight compounds such as PD173074 (N-[2-[[4-(Diethylamino)butyl]amino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)urea) or SU5402 (2-[(1,2-Dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-1H-pyrrole-3-propanoic acid), which inhibit the tyrosine kinase activity of FGF receptors by competing for ATP). These substances may be used alone or in combination of two or more. PD173074 and SU5402 are known FGF receptor inhibitors and are available commercially. PD173074 and SU5402 are preferred FGF receptor inhibitors.
[0037] The MEK inhibitor is not particularly limited as long as it inhibits the expression or activity of the MEK family, and may be any of a protein, nucleic acid, or low-molecular-weight compound. Representative examples of the MEK family include MEK1, MEK2, MEK3, etc., and the MEK inhibitor is a substance that inhibits the expression or activity of one, several, or all of these MEK family members. Examples of such substances include substances that suppress the expression of genes encoding various MEKs (e.g., antisense oligonucleotides, siRNA, etc.), and substances that inhibit the enzymatic activity of various MEKs [PD0325901 (N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide), PD184352 ((2-[(2-Chloro-4-iodophenyl)amino]-N-cyclopropylmethoxy)-3,4-difluorobenzamide), PD98059 (2'-Amino-3'-Methoxyflavone), U 0126 (1,4-Diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene), MEK162(5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N- (2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide), SL327 (α-[Amino[(4-aminophenyl)thio]methylene]-2-(trifluoro methyl)benzeneacetonitrile), TAK-733 ((R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido [2,3-d]pyrimidine-4,7(3H,8H)-dione) or AZD-8330 (2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide), and other small molecular weight compounds.These substances may be used alone or in combination of two or more. PD0325901, PD184352, PD98059, U0126, MEK162, SL327, TAK-733, and AZD-8330 are known MEK inhibitors, and are commercially available as appropriate. Preferred examples of MEK inhibitors include PD0325901, PD184352, U0126, TAK-733, and AZD-8330.
[0038] The nodal signaling pathway inhibitor is not particularly limited as long as it can suppress nodal-mediated signal transduction, and may be any of a protein, a nucleic acid, or a low-molecular-weight compound. Nodal-mediated signals are transmitted via nodal receptors. Nodal receptors exist as heterodimers of type I receptors (ALK (activin receptor-like kinase)-4, ALK-5, ALK-7) and type II receptors (ActRII). Examples of inhibitors of the Nodal signaling pathway include, but are not limited to, substances that act directly on Nodal or Nodal receptors (anti-Nodal antibodies, anti-Nodal receptor antibodies, etc.), substances that suppress the expression of genes encoding Nodal or Nodal receptors (e.g., antisense oligonucleotides, siRNA, etc.), substances that inhibit the binding of Nodal receptors to Nodal (Lefty-A, Lefty-B, Lefty-1, Lefty-2, soluble Nodal receptors, etc.), and substances that inhibit physiological activities resulting from signal transduction by Nodal receptors [such as small molecular weight compounds such as SB-431542 (SB431542) (4-[4-(1,3-Benzodioxol-5-yl)-5-(pyridin-2-yl)-1H-imidazol-2-yl]benzamide), which inhibits the kinase activity of type I receptors by competing for ATP]. SB-431542 is a known nodal signal inhibitor and is appropriately available as a commercial product, etc. Preferred examples of nodal signal inhibitors include SB-431542.
[0039] The Wnt signaling pathway inhibitor is not particularly limited as long as it can suppress signal transduction mediated by Wnt, and may be any of a protein, a nucleic acid, a low molecular weight compound, etc. Wnt-mediated signals are transmitted via the Wnt receptor, which exists as a heterodimer of Frizzled (Fz) and LRP5 / 6 (low-density lipoprotein receptor-related protein 5 / 6). Examples of inhibitors of the Wnt signaling pathway include substances that act directly on Wnt or Wnt receptors (anti-Wnt antibodies, anti-Wnt receptor antibodies, etc.), substances that suppress the expression of genes encoding Wnt or Wnt receptors (e.g., antisense oligonucleotides, siRNA, etc.), substances that inhibit the binding of Wnt receptors to Wnt (soluble Wnt receptors, dominant-negative Wnt receptors, Wnt antagonists, Dkk1, Cerberus protein, etc.), and substances that inhibit physiological activities resulting from signal transduction by Wnt receptors [casein kinase I inhibitors CKI-7 (N-(2-Aminoethyl)-5-chloroisoquinoline-8-sulfonamide) and D4476 (4-[4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benz ... nzamide), IWR-1-endo (IWR1e) (4-[(3aR,4S,7R,7aS)-1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-yl]-N-8-quinolinyl-benzamide), which stabilizes the β-catenin degradation complex by inhibiting Axin turnover, and membrane-bound O-acyltransferase (M Examples of such compounds include, but are not limited to, small molecular weight compounds such as IWP-2 (N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin-2-yl)thio]acetamide), which inactivates porcupine (Porcn), a benzothiazolinone-3-oxoat (BOAT), and suppresses palmitylation of Wnt proteins.CKI-7, D4476, IWR-1-endo (IWR1e), IWP-2, etc. are known Wnt signal inhibitors, and are appropriately available as commercially available products, etc. A preferred example of a Wnt signal inhibitor is CKI-7.
[0040] As used herein, "Eye Field Transcription Factors" refer to genes that are expressed in the eye-forming region in the early stages of development, and ET (Tbx3), Rx1 (Rax), Pax6, Six3, Lhx2, Tlx (Nr2e1), Optx2 (Six6), and the like have been identified. These eye-forming transcription factors can be used as markers for the early stages of eye formation.
[0041] The number of days for the first step is not particularly limited as long as the cells generated by exposing pluripotent stem cells to the FGF receptor inhibitor and / or MEK inhibitor, etc., retain their ability to differentiate into retinal pigment epithelial cells, but the pluripotent stem cells in the first step are cultured for no more than 30 days. This period may vary depending on the pluripotent stem cell strain used, but is usually 2 days or more, preferably 3 days or more, and more preferably 4 days or more. The pluripotent stem cells in the first step are more preferably cultured for 2 to 13 days or 2 to 6 days, and even more preferably 4 to 6 days.
[0042] The culture period in the second step is not particularly limited as long as it is a period that allows the desired retinal pigment epithelial cells to be induced, but an example of such a culture period is that retinal pigment epithelial cells can usually be generated on day 14 to 40 counting from the start of step 2. Furthermore, those skilled in the art can confirm the generation of retinal pigment epithelial cells based on the expression of cell markers (RPE65 (retinal pigment epithelial cells), Mitf (retinal pigment epithelial cells), BEST1 (retinal pigment epithelial cells), CRALBP (retinal pigment epithelial cells), etc.), the presence of melanin granules (black-brown), tight junctions between cells, characteristic polygonal / cobblestone-like cell morphology, etc., and the culture period can be set by confirming these.
[0043] After the second step, the medium is preferably replaced with a maintenance medium for retinal pigment epithelial cells, followed by further culturing. For example, the culture is continued for approximately 5 to 20 days, with the entire medium being replaced at least once every three days. The maintenance medium for retinal pigment epithelial cells can be, for example, the one described in IOVS, March 2004, Vol. 45, No. 3, Masatoshi Haruta, et al.; IOVS, November 2011, Vol. 52, No. 12, Okamoto and Takahashi; J. Cell Science 122 (17), Fumitaka Osakada, et al.; and IOVS, February 2008, Vol. 49, No. 2, Gamm, et al., which is composed of a basal medium, serum and / or serum substitute, and other components.
[0044] It is also possible to produce retinal pigment epithelial cells by omitting the first step and performing only the second step.
[0045] When retinal pigment epithelial cells are produced by adhesion culture, they can adhere to each other and form a sheet-like structure. Therefore, it is possible to produce a sheet of retinal pigment epithelial cells that can be transplanted into patients. Furthermore, the sheet of retinal pigment epithelial cells (hereinafter sometimes referred to as "RPE sheet") can be prepared by dispersing the retinal pigment epithelial cells as independent, single cells (single cells) using methods well known to those skilled in the art, such as using enzymes such as trypsin, and then suspending these in the transplantation medium of the present invention to prepare a suspension that can be transplanted into patients.
[0046] "Adhesion culture" refers to culture carried out under conditions that allow cells or cell aggregates to adhere to cultureware, etc. In this case, cell adhesion means that strong cell-substrate bonds are formed between the cells or cell aggregates and the cultureware, etc. In other words, adhesion culture refers to culture under conditions that allow strong cell-substrate bonds to be formed between the cells or cell aggregates and the cultureware, etc. Those skilled in the art can appropriately set culture conditions for the cultureware, etc., and carry out adhesion culture.
[0047] Retinal pigment epithelial cells can also be produced by suspension culture. Specifically, embryonic bodies (also known as EBs) can be produced from pluripotent stem cells, and these can be induced to differentiate into retinal pigment epithelial cells to produce cell aggregates containing retinal pigment epithelial cells. The cell aggregates can be dispersed by methods well known to those skilled in the art, such as using enzymes such as trypsin, to recover retinal pigment epithelial cells as independent, single cells. These can then be suspended in a transplantation medium to prepare a suspension suitable for transplantation into patients.
[0048] 2. Transplantation Medium The transplantation medium of the present invention is a transplantation medium for subretinal transplantation of retinal pigment epithelial cells, and has a viscosity of 1 to 6 mPa·s, preferably 1.3 to 5.5 mPa·s, 1.5 to 4 mPa·s, and more preferably 2 to 3 mPa·s at 25°C and a shear rate of 2 (1 / s), and may contain hyaluronic acid and a pharmaceutically acceptable aqueous liquid. By using the above-mentioned predetermined viscosity range, cell leakage into the vitreous body and prolonged retinal detachment can be suppressed when retinal pigment epithelial cells are transplanted subretinal, thereby reducing side effects such as preretinal membrane and retinal detachment and improving the engraftment of retinal pigment epithelial cells at the transplant site.
[0049] The transplant medium of the present invention preferably has a viscosity of 3 mPa·s or less, preferably 2 mPa·s or less, at a shear rate of 1000 (1 / s) at 25°C, and the difference in viscosity between a shear rate of 1 (1 / s) and a shear rate of 10 (1 / s) at 25°C is 0.3 to 2.0 mPa·s, preferably 0.4 to 1.8 mPa·s, 0.5 to 1.5 mPa·s, or 0.6 to 1.3 mPa·s. In one embodiment, the viscosity at a shear rate of 1000 (1 / s) at 25°C is 1 mPa·s or more, 1.1 mPa·s or more, or 1.2 mPa·s or more.
[0050] The transplant medium of the present invention may contain chondroitin sulfate, but preferably does not contain chondroitin sulfate. Both hyaluronic acid and chondroitin sulfate are mucopolysaccharides present in living bodies and function as thickening components of the transplant medium.
[0051] As used herein, hyaluronic acid refers to a linear polymeric polysaccharide with a molecular weight of tens of thousands to millions, which has a structure in which D-glucuronic acid and D-N-acetylglucosamine are alternately linked by β-1,4 and β-1,3 glycosidic bonds. Hyaluronic acid has high water retention capacity and viscosity, and is a substance widely used in pharmaceuticals, cosmetics, and the like. As used herein, "hyaluronic acid" refers to a concept that includes both free hyaluronic acid and its salts. Examples of hyaluronic acid salts include alkali metal salts and alkaline earth metal salts of hyaluronic acid. Specifically, commercially available salts such as sodium hyaluronate and potassium hyaluronate can be used.
[0052] Chondroitin sulfate is a mucopolysaccharide having a structure in which sulfate is bound to a sugar chain consisting of repeating disaccharides of D-glucuronic acid (GlcA) and N-acetyl-D-galactosamine (GalNAc). In this specification, "chondroitin sulfate" refers to a concept that includes both free chondroitin sulfate and its salts. Examples of chondroitin sulfate salts include alkali metal salts and alkaline earth metal salts of chondroitin sulfate. Specifically, commercially available chondroitin sulfate, sodium chondroitin sulfate, potassium chondroitin sulfate, etc. can be used.
[0053] As hyaluronic acid or its salt, commercially available aqueous solution of hyaluronic acid or its salt can be used.Specifically, Viscoat (registered trademark) 0.5 ocular viscoelastic agent contains sodium hyaluronate 3%, chondroitin sulfate sodium ester 4%, sodium dihydrogen phosphate monohydrate, anhydrous sodium dihydrogen phosphate and isotonicity agent as its components, Provisc (registered trademark) 0.85 ocular viscoelastic agent contains sodium hyaluronate 1%, anhydrous sodium dihydrogen phosphate, sodium dihydrogen phosphate monohydrate, pH adjuster (two components) and isotonicity agent as its components, sodium hyaluronate 0.6%, sodium chloride, dihydrogen phosphate. Examples of such ophthalmic solutions include OPEGAN (registered trademark) 0.6 ophthalmic viscoelastic solution, which contains sodium and sodium hydrogen phosphate as ingredients; OPEGAN (registered trademark) 1.1 ophthalmic viscoelastic solution, which contains 1.1% sodium hyaluronate, sodium chloride, sodium dihydrogen phosphate, and sodium hydrogen phosphate as ingredients; and Hyalein Mini (registered trademark) eye drops 0.3%, which contains 0.3% sodium hyaluronate, epsilon-aminocaproic acid, sodium edetate hydrate, potassium chloride, sodium chloride, and a pH adjuster as ingredients. Commercially available aqueous solutions of hyaluronic acid or its salts preferably do not contain any viscosity-influencing substances (e.g., thickeners) other than hyaluronic acid and chondroitin sulfate, and more preferably do not contain any viscosity-influencing substances (e.g., thickeners) other than hyaluronic acid.
[0054] The "pharmaceutically acceptable aqueous liquid" in the transplantation medium of the present invention is not particularly limited as long as it is an aqueous solution that can be administered to a living body and has physical properties suitable for transplantation, and may be, for example, an aqueous solution containing a buffer solution, an infusion solution, physiological saline, water for injection, a perfusion solution, etc. A buffer solution is preferred.
[0055] An example of a "pharmaceutically acceptable aqueous liquid" is an aqueous solution containing balanced salts (i.e., a balanced salt solution). The aqueous solution containing balanced salts may contain an appropriate buffer, tonicity agent, pH adjuster, antioxidant, chelating agent, etc., within a range that does not affect the viability of the transplanted retinal tissue.
[0056] Examples of the buffer include phosphate buffer, borate buffer, citrate buffer, tartrate buffer, acetate buffer, amino acid, epsilon-aminocaproic acid, and the like.
[0057] Examples of isotonic agents include sugars such as sorbitol, glucose, and mannitol, polyhydric alcohols such as glycerin and propylene glycol, salts such as sodium chloride, and boric acid.
[0058] Chelating agents include sodium edetate and citric acid.
[0059] Examples of pH adjusters include sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogencarbonate, boric acid or a salt thereof (borax), hydrochloric acid, citric acid or a salt thereof (sodium citrate, sodium dihydrogen citrate, etc.), phosphoric acid or a salt thereof (disodium hydrogen phosphate, potassium dihydrogen phosphate, etc.), acetic acid or a salt thereof (sodium acetate, ammonium acetate, etc.), and tartaric acid or a salt thereof (sodium tartrate, etc.).
[0060] Examples of antioxidants include ascorbic acid, glutathione, sodium hydrogen sulfite, dried sodium sulfite, sodium pyrosulfite, and tocopherol.
[0061] Specific examples of "pharmaceutically acceptable aqueous liquids" include aqueous solutions containing one or more components selected from sugars such as glucose, inorganic salts such as calcium chloride, sodium chloride, magnesium chloride, potassium chloride, and magnesium sulfate, inorganic substances such as sodium bicarbonate, sodium acetate, sodium citrate, sodium dihydrogen phosphate, sodium hydrogen phosphate, anhydrous sodium monohydrogen phosphate, and hydrochloric acid, and chelating agents such as edetates (e.g., sodium edetate).
[0062] To prepare a pharmaceutically acceptable aqueous liquid, commercially available intraocular irrigation and irrigation solutions can be used. Specifically, examples of intraocular irrigation and irrigation solutions include an aqueous solution containing 1.5 mg of glucose, 6.6 mg of sodium chloride, 0.36 mg of potassium chloride, 0.18 mg of calcium chloride hydrate, 0.3 mg of magnesium sulfate hydrate, and 2.1 mg of sodium bicarbonate per mL, as well as additives such as sodium citrate hydrate, sodium acetate hydrate, and hydrochloric acid, commercially available as Opeguard® MA Ocular Irrigation Solution (Senju Pharmaceutical Co., Ltd.), or oxyglutathione ocular irrigation solution. Furthermore, to prepare a pharmaceutically acceptable aqueous liquid, Hank's balanced salt solution (HBSS), Eagle's balanced salt solution (EBSS), phosphate-buffered saline (PBS), Dulbecco's phosphate-buffered saline (DPBS), and the like can also be used.
[0063] One embodiment of the transplantation medium of the present invention is a transplantation medium containing only hyaluronic acid as a thickening component. Specifically, for example, it can be prepared by diluting 1% Provisc® 0.85 ocular viscoelastic agent (Alcon Japan Co., Ltd.), which contains 10 mg / mL of sodium hyaluronate but does not contain chondroitin sulfate, 20 to 200 times (preferably 50 to 150 times, or about 100 times) with a balanced salt solution such as HBSS. Alternatively, it can be prepared by diluting Viscoat® 0.5 ocular viscoelastic agent 20 to 200 times (preferably 50 to 150 times, or about 100 times) with a balanced salt solution such as HBSS.
[0064] One embodiment of the transplantation medium of the present invention can be prepared by diluting Viscoat (registered trademark) 0.5 ocular viscoelastic agent (Alcon Japan Co., Ltd.), which contains 30 mg / mL of sodium hyaluronate and 40 mg / mL of sodium chondroitin sulfate, 20 to 200 times (preferably 50 to 150 times, or about 100 times) with a balanced salt solution such as HBSS.
[0065] One embodiment of the transplantation medium of the present invention can be prepared by diluting OPEGAN (registered trademark) 0.6 ophthalmic viscoelastic agent 20 to 200 times with an aqueous liquid such as Opeguard. Another embodiment can be prepared by diluting, for example, Hyalein Mini (registered trademark) 0.3% ophthalmic solution 6 to 60 times with an aqueous liquid such as Opeguard.
[0066] One embodiment of the transplant medium of the present invention includes a transplant medium containing hyaluronic acid as a viscosity-increasing component. Chondroitin sulfate may also be included. The concentrations of hyaluronic acid and chondroitin sulfate are not particularly limited, as long as the viscosity of the transplant medium at a shear rate of 2 (1 / s) at 25°C can be maintained at 1.5 to 4 mPa·s, preferably 2 to 3 mPa·s. One embodiment of the transplant medium of the present invention includes a transplant medium containing 0.005 w / v% to 0.15 w / v% (e.g., 0.007 w / v% to 0.04 w / v%, 0.008 w / v% to 0.035 w / v%, 0.009 w / v% to 0.03 w / v%, or approximately 0.01 w / v%) of hyaluronic acid having an average molecular weight of 500,000 to 3.9 million (preferably 1.5 million to 3.9 million). Further examples include transplantation media containing more than 0 w / v % (e.g., 0.001 w / v %) to 0.20 w / v % (or 0.1 w / v %, 0.05 w / v %) of chondroitin sulfate or a salt thereof having a molecular weight of 20,000 to 24,000. As described above, the transplantation medium of the present invention more preferably does not contain chondroitin sulfate.
[0067] The transplant medium of the present invention preferably does not contain any viscosity-influencing substances other than hyaluronic acid and chondroitin sulfate (e.g., thickeners (thickening components)), or any viscosity-influencing substances other than hyaluronic acid (e.g., thickeners (thickening components)). Examples of thickeners include gum arabic, karaya gum, xanthan gum, casein, agar, alginic acid, α-cyclodextrin, dextrin, dextran, carrageenan, gelatin, collagen, pectin, starch, chitin and its derivatives, chitosan and its derivatives, elastin, heparin, heparinoid, heparin sulfate, heparan sulfate, hyaluronic acid, polysaccharides or derivatives thereof such as methylcellulose and hydroxyethylcellulose, ceramide, macrogol, glycerin, povidone, poly(vinyl methacrylate), poly(vinyl alcohol), polyacrylic acid, carboxymethyl polymer, and polyethyleneimine.
[0068] The implantation vehicle of the present invention is preferably free of antimicrobial agents and preservatives.
[0069] Here, physical properties suitable for transplantation include pH and osmotic pressure. The pH of the transplantation medium is not particularly limited as long as it is in the neutral range, and the transplantation medium of the present invention may be adjusted to a pH of 6.5 to 8.0, preferably about pH 7.0 to 7.5. The osmotic pressure of the transplantation medium may be hypotonic, isotonic, or hypertonic, with a value close to isotonic being preferred. The osmotic pressure ratio may be adjusted to 0.7 to 1.3, preferably 0.9 to 1.1.
[0070] Furthermore, the transplantation medium of the present invention can be preferably sterilized before use, for example by filtration sterilization using a membrane filter or the like.
[0071] 3. Transplantation Composition The transplantation composition of the present invention comprises retinal pigment epithelial (RPE) cells for transplantation and the transplantation medium of the present invention. The transplantation composition of the present invention may be a cell suspension obtained by suspending retinal pigment epithelial cells for transplantation in the transplantation medium. The transplantation medium of the present invention is as described in 2. Transplantation Medium above. As the retinal pigment epithelial cells for transplantation, the retinal pigment epithelial cells described in 1. Definition can be used, and retinal pigment epithelial cells derived from human iPS cells are preferred.
[0072] The retinal pigment epithelial cells are not particularly limited in their state, as long as they are transplantable. In one embodiment, the retinal pigment epithelial cells that can be transplanted into a patient may be a sheet of retinal pigment epithelial cells, dispersed retinal pigment epithelial cells, or a combination thereof. The retinal pigment epithelial cells may be dispersed retinal pigment epithelial cells that do not contain a sheet.
[0073] In the transplant composition, the retinal pigment epithelial cells for transplantation are 1 × 10 6 cells / mL~5×10 7 Preferably, the concentration is 2.5 x 10 cells / mL. 6 cells / mL ~ 1.5 x 10 7 cells / mL, 5 x 10 6 cells / mL ~ 1 x 10 7 For one transplant, the volume (administration volume) of the transplant composition is preferably 10 μL to 100 μL, and more preferably, for example, 20 μL to 80 μL, 10 μL to 70 μL, 20 μL to 50 μL, or 30 μL to 50 μL. For example, 0.2×10 5 cells ~5×10 5 cells, 1 x 10 5 cells ~5×10 5 The transplantation composition of the present invention may be a cell suspension containing the above-mentioned concentration of retinal pigment epithelial cells for transplantation.
[0074] The transplantation composition of the present invention is a composition for transplanting (or administering) RPE cells under the retina of the eye. The recipient of the transplantation composition of the present invention may be a mammal (e.g., human, dog, cat, mouse, rat, etc., preferably human) with a disease based on impairment of retinal pigment epithelial cells or damage to retinal pigment epithelial cells, for example, a mammal (e.g., human, mouse, rat, etc., preferably human) with a retinal disease or retinal damage such as macular degeneration (e.g., atrophic and exudative age-related macular degeneration), hereditary retinal disease, degeneration of the retinal pigment epithelium (including retinitis pigmentosa and crystalline retinopathy), deletion defects / breaks in the retinal pigment epithelium, macular dystrophy (including Stargardt's disease), cone dystrophy, rod dystrophy, or cone-rod dystrophy, and particularly preferably a human with macular degeneration, degeneration / deletion defects / breaks in the retinal pigment epithelium, etc.
[0075] When the transplant composition of the present invention is used for the treatment of retinitis pigmentosa, it may be used, for example, for the treatment of corrected visual acuity of less than 0.7, preferably less than 0.2.
[0076] When the transplant composition of the present invention is used to treat retinitis pigmentosa, examples include diseases with visual field constriction, such as diseases in which a central 20-degree visual field remains in a static visual field test (which can be tested by Humphrey visual field test), preferably diseases in which a central 10-degree visual field remains in a static visual field test (which can be tested by Humphrey visual field test), and more preferably diseases in which a central 5-degree visual field remains in a static visual field test (which can be tested by Humphrey visual field test).
[0077] When the transplant composition of the present invention is used for the treatment of retinitis pigmentosa, it is preferably used for the treatment of a patient with an MD value of less than -30 dB in the Humphrey visual field test (10-2).
[0078] The method of subretinal transplantation (administration) is not particularly limited as long as it is a known method, and examples thereof include injection using a syringe of an appropriate size or a transplantation device including a needle or resin portion. More specifically, examples include the transvitreal method and the transchoroidal method. An overview of the transvitreal method is shown in FIG. 1 , and as described in Example 1, it is performed by using a cataract / vitreous surgery device to perform vitrectomy including removal of the posterior vitreous membrane, followed by injection of an appropriate amount of the transplant composition into the subretinal space (between the sensory retina and the retinal pigment epithelial cells) to form blebs (hydraulically debridement retinal detachments). Thereafter, air replacement of the vitreous cavity may be performed as necessary. In addition to the method of forming a bleb by injecting the transplant composition itself, there is also a method of first injecting an ocular irrigation solution (such as HBSS) to form a bleb, and then aspirating the liquid from the bleb as needed, followed by injecting the transplant composition.
[0079] The transchoroidal method is a method of approaching from the outside of the eyeball, in which a part of the sclera is incised and peeled off, a catheter is inserted into the choroidal space from there, and an appropriate amount of the transplant composition is injected under the retina to administer the composition.
[0080] In the transvitreal cavity approach, several holes are made in the sclera to allow for the insertion of surgical instruments. The transplant composition of the present invention can be administered (injected) using a needle, syringe, or the like, making it a minimally invasive method among transvitreal cavity approaches. When administering the transplant composition of the present invention by the transvitreal cavity approach, the transplant composition of the present invention may be administered to the affected area through the holes in the sclera while forming a bleb.
[0081] The administration needle is not particularly limited, but examples thereof include a metal bevel needle and a polytip needle. A polytip needle is particularly preferred. In one embodiment, the outer diameter of the administration needle may be 38 gauge, 39 gauge, or 40 gauge.
[0082] In the transvitreal approach, there is a possibility that the transplant composition or retinal pigment epithelial cells for transplantation may leak from the bleb into the vitreous, and the leaked retinal pigment epithelial cells may form a preretinal membrane. On the other hand, in the transchoroidal approach, unless a hole is drilled on the retinal side, there is almost no leakage of the transplant composition into the vitreous. However, when administering a liquid into a narrow area with a needle, there is a possibility that a hole may be drilled on the retinal side, and therefore, even in the transchoroidal approach, there is a possibility that retinal pigment epithelial cells leaking from the bleb may form a preretinal membrane. Furthermore, both the transvitreal approach and the transchoroidal approach can cause retinal detachment. Possible side effects of subretinal administration include the formation of a preretinal membrane and prolonged retinal detachment. The transplant medium in the transplant composition of the present invention has a specific viscosity, which can suppress cell leakage into the vitreous and prolonged retinal detachment.
[0083] The transplantation method (administration method) for the transplantation medium or transplantation composition of the present invention is preferably the vitreous cavity method, and after the subretinal transplantation via the vitreous cavity method, it is preferable to replace the vitreous with air.
[0084] One aspect of the present invention is a method for treating a disease caused by damage to retinal pigment epithelial cells or a damaged state of retinal pigment epithelial cells, comprising transplanting the transplant composition of the present invention into a subject requiring transplantation (e.g., subretinal area of an eye suffering from an ophthalmic disease). The transplant composition of the present invention can be used as a therapeutic agent for a disease caused by damage to retinal pigment epithelial cells or to replenish the damaged site in the case of such a damaged state of retinal pigment epithelial cells. By transplanting the transplant composition of the present invention into a patient requiring transplantation who has a disease caused by damage to retinal pigment epithelial cells or a patient with a damaged state of retinal pigment epithelial cells, and replenishing the retinal pigment epithelial cells or damaged retinal pigment epithelial cells, the disease caused by damage to retinal pigment epithelial cells or the damaged state of retinal pigment epithelial cells can be treated.
[0085] 4. Uses, Therapeutic Agents, and Treatment Methods One aspect of the present invention provides use of a transplantation medium of the present invention, which has a viscosity of 1.5 to 4 mPa·s at a shear rate of 2 (1 / s) at 25° C. and contains hyaluronic acid and a pharmaceutically acceptable aqueous liquid, for subretinal transplantation of retinal pigment epithelial cells. Another aspect of the present invention provides a transplantation medium of the present invention for use in subretinal transplantation of retinal pigment epithelial cells.
[0086] In one aspect, the present invention provides a therapeutic agent for a disease caused by damage to retinal pigment epithelial cells, comprising the transplant composition of the present invention. The damage to retinal pigment epithelial cells and the dosage are as described above.
[0087] The therapeutic agent of the present invention may be administered in combination with an immunosuppressant. Those skilled in the art will be able to select the immunosuppressant to be used in transplantation.
[0088] The therapeutic agent of the present invention may be a cell suspension prepared at a medical institution using a transplantation medium and retinal pigment epithelial cells. In this case, the retinal pigment epithelial cells may be frozen and delivered to the medical institution as a frozen preparation containing retinal pigment epithelial cells. It is preferable that the retinal pigment epithelial cells are frozen in a dispersed state. The method for cryopreserving retinal pigment epithelial cells is not particularly limited, as long as it is a method generally known for cryopreserving cells. For example, the retinal pigment epithelial cells can be frozen at −80°C using a commercially available cell cryopreservation solution, StemCellBanker (Zenoaq), and then cryopreserved using liquid nitrogen or the like. At the time of use, the frozen preparation may be thawed at the time of use at a medical institution and suspended in a transplantation medium or the like for use in transplantation therapy. After thawing the frozen preparation, the cells may be washed with a buffer solution, such as the transplantation medium, before being suspended in the transplantation medium or the like.
[0089] In one aspect of the present invention, there is provided a method for treating a disease caused by damage to retinal pigment epithelial cells, comprising the step of administering an effective amount of the transplant composition of the present invention or an effective amount of the therapeutic agent of the present invention to a patient in need thereof.
[0090] The method for administering the transplant composition or therapeutic agent of the present invention is not particularly limited as long as it is a known method, and examples thereof include the above-mentioned transvitreal method and transchoroidal method, with the transvitreal method being preferred.
[0091] A human subject is administered local anesthesia (sub-Tenon anesthesia / retrobulbar anesthesia) or general anesthesia. When administering a composition for implantation or a therapeutic agent via the intravitreal cavity, a vitrectomy is performed using an appropriate vitreous surgery device (e.g., a Constellation Vision System). If necessary, triamcinolone acetonide (0.5 to 4 mg) may be injected into the vitreous cavity for the purpose of visualizing the vitreous. The composition for implantation or the therapeutic agent may be administered to the affected area through a hole in the sclera to form a bleb. When the administration method includes forming a bleb, the method may further comprise irrigating the vitreous cavity and replacing the vitreous cavity of the human subject with air after administration.
[0092] In the treatment method of the present invention, immunosuppressants may be administered in combination.
[0093] After the treatment method of the present invention, it is preferable to rest in a supine position for at least 12 hours.
[0094] As an effect of administering (transplanting) the composition for transplantation or therapeutic agent of the present invention or implementing the treatment method, retinal pigment epithelial cells are engrafted at the administration site of the recipient (e.g., human) and an adhesion structure with the photoreceptor layer is reconstructed. As a result, the transplanted retinal pigment epithelial cells function, and visual function is restored or prevented from further deterioration and maintained compared to before the administration of the therapeutic agent or before the implementation of the treatment method.
[0095] The effectiveness of the treatment can be confirmed through the ophthalmologic examinations described above. It can also be evaluated using health-related quality of life (QOL) scales. These scales comprehensively evaluate health status from physical, mental, and social aspects, and some scales are specific to visual function. Examples include the Visual Function Questionnaire (VFQ-25), Euro-QOL 5 Dimension-5 Level (EQ-5D-5L), and Health Utilities Index Mark 3 (HUI3).
[0096] Example 1: Examination of the Effects on Cell Leakage Using Enucleated Pig Eyes. Using pig eyes with an eyeball size similar to that of humans, the effects of transplantation medium viscosity and postoperative air replacement in the vitreous cavity on cell leakage were examined ex vivo. Human iPS cell (QHJI01s04 strain)-derived retinal pigment epithelial (RPE) cells, produced using a method similar to that of Kuroda et al. (Stem Cell Res. 2019;39:101514), were used in all examples. Pig eyes extracted from slaughter pigs were obtained on the same day, and if fundus observation was difficult due to lens opacity, the lens was removed as necessary. A suspension of human iPS cell-derived RPE cells was administered subretinally (transplanted) using the method described below.
[0097] Subretinal injection of the RPE cell suspension was performed according to the standard vitreous surgery procedure (transvitreal approach), as shown in the schematic diagram in Figure 1. Using a cataract and vitreous surgery device (Constellation Vision System LTX, manufactured by Alcon Japan), 0.5-4 mg of triamcinolone acetonide (Fujifilm Wako Pure Chemical Industries, Ltd., 209-10961) was injected intravitreously to visualize the vitreous. A posterior vitreous membrane peel was created from the macular area, and peripheral vitrectomy was performed. An ophthalmic surgical syringe and needle adapter was connected to the vitreous surgery device using appropriate tubing, and the RPE cell suspension was injected. After removing air from the tip using the ejection function of the vitreous surgery device, a subretinal injection needle (Medone Cannula: Tapered Cannula, Polytip 25G / 38G, 3219, Medone Surgical, Inc. / Japan Surgery Co., Ltd.) was connected. A subretinal injection needle was inserted through the port, and an appropriate amount of the RPE cell suspension was injected subretinally. Subretinal injection of the RPE cell suspension resulted in the formation of a bleb. After administration, the vitreous cavity was thoroughly washed and, if necessary, ventilated.
[0098] The administered RPE cell suspension consisted of 5.7 × 10 RPE cells labeled with the fluorescent labeling reagent PKH26 Red Fluorescent Cell Linker Mini Kit (Sigma-Aldrich, MINI26) in two types of transplantation media. 7 / mL (air replacement condition) or 6.0 x 10 6The cells were suspended at a concentration of 1000 cells / mL (without air replacement). Viscous medium: a medium (7-fold dilution) in which Viscoat 0.5 ocular viscoelastic agent (manufactured by Alcon Japan) and Hank's balanced salt solution HBSS(+) (manufactured by Thermo Fisher Scientific, 14025092) were mixed at a ratio of 1:6. Buffer-only medium: a medium containing only HBSS(+).
[0099] After administration, the sample was left to stand for several hours, and the corneal hemisphere was removed. The fundus was then observed under a stereofluorescence microscope (Leica Microsystems, Leica M165FC). The results are shown in Figure 2. Figure 2 demonstrates that the addition of hyaluronic acid to the medium reduced cell leakage. Furthermore, no cell leakage was observed when air replacement of the vitreous was performed.
[0100] Furthermore, subretinal injections were performed by varying the dilution ratio of Viscoat in the medium from 7 to 21 times. It was found that when the concentration of Viscoat was high (the dilution ratio was low), the resistance during ejection increased, making it difficult to form a bleb. It was also confirmed that up to approximately 100 μL of the administered solution could be administered, but backflow from the injection port was observed as the administered amount increased. The RPE cell concentration was 5.7 × 10 7 It was confirmed that suspensions up to 1000 / mL could be administered without any problems.
[0101] Example 2: Transplantation Experiment in Cynomolgus Monkeys To prevent cell leakage and improve cell engraftment under the retina, we investigated administration methods using cynomolgus monkeys, whose ocular anatomical characteristics are very similar to those of humans. Human iPS cell-derived RPE cells suspended in transplantation media prepared by diluting HBSS(+) alone (same as above) or Provisc® 0.85 ocular viscoelastic agent 1% (Alcon Japan Co., Ltd.) (hereinafter referred to as Provisc) or Viscoat® 0.5 ocular viscoelastic agent (Alcon Japan Co., Ltd.) (hereinafter referred to as Viscoat) 20-, 100-, or 200-fold with HBSS(+) were administered under the retina of cynomolgus monkeys to determine the appropriate transplantation media composition. Furthermore, the effects of postoperative air replacement of the vitreous cavity were also investigated. Here, Viscoat contains 30 mg / mL of sodium hyaluronate and 40 mg / mL of sodium chondroitin sulfate, while Provisc contains 10 mg / mL of sodium hyaluronate but does not contain chondroitin sulfate.
[0102] Cambodian cynomolgus monkeys (2.0-5.0 kg at the start of acclimation) were used in this study. One to two drops of tropicamide-phenylephrine hydrochloride ophthalmic solution (Midrin P ophthalmic solution, Santen Pharmaceutical Co., Ltd.) and phenylephrine hydrochloride ophthalmic solution (Neocynedin Kowa 5% ophthalmic solution, Kowa Co., Ltd.) were instilled into the right eye to dilate the pupil. Combined anesthesia was administered intramuscularly with 10 mg / kg of ketamine hydrochloride (Ketalar 500 mg for intramuscular injection, Daiichi Sankyo Propharma Co., Ltd.) and 0.08 mg / kg of medetomidine hydrochloride (Domitor, Orion Corporation). After endotracheal intubation, controlled ventilation was performed using a mixture of oxygen and 0.5-2.0% isoflurane (isoflurane inhalation anesthetic solution "Pfizer," Mylan Pharmaceuticals Co., Ltd.). The animals were fixed on the operating table in a supine position, and an RPE cell suspension (2.5 × 10 6 ~1.5 x 10 7An appropriate amount (50-100 μL) of the suspension (100 μL / mL) was administered. After administration, if any leakage occurred, the leaked fluid was aspirated. Furthermore, the vitreous cavity was purged with air as in Example 1, if necessary. To promote cell settling and engraftment, the patient was maintained in a supine position under inhalation anesthesia for up to 3 hours. To suppress rejection, immunosuppression was performed using a once-daily intramuscular injection of cyclosporine (Sandimmune 250 mg for intravenous infusion, Novartis Pharma K.K.) in combination with intraoperative sub-Tenon administration of triamcinolone acetonide (MacuAid 40 mg for ophthalmic injection, Wakamoto Pharmaceutical Co., Ltd.). After administration, the administered eye was observed over time using a fundus camera (Kowa Optimed, VX-10α) and an OCT device (Heidelberg Engineering, Spectralis OCT2).
[0103] The results of subretinal administration in cynomolgus monkeys are shown. Cell concentration: 1.5 x 10 7 When a suspension of 1.0 × 10 cells / mL was used, the visibility of the injection needle tip decreased during injection in all media. 7 Administration was possible without problems at cell concentrations of 0.1 cells / mL or less. Furthermore, it was confirmed that administration volumes of 50 to 100 μL could be administered subretinally in one eye, and that administration volumes of 70 to 80 μL were reproducibly and stably possible.
[0104] The results of OCT findings up to 4 weeks later are shown in Tables 1 and 2. Tables 1 and 2 show that epiretinal membrane (ERM) formation was observed in 7 of 8 cases in which the vitreous cavity was not air-substituted, and in 8 of 23 cases in which the vitreous cavity was air-substituted, indicating the possibility that air substitution can suppress leakage of the cell suspension and reduce the formation of the epiretinal membrane.
[0105] Furthermore, in the group receiving the transplantation medium containing Provisc or Viscoat diluted 20-fold, prolonged retinal detachment around the injection site was observed in 8 of 10 cases. However, in the other treatment groups, retinal reattachment at the injection site was confirmed approximately 4 weeks after administration, except for one case receiving Provisc diluted 200-fold. The medium containing Provisc or Viscoat diluted 20-fold did not exhibit any inhibitory effect on preretinal membrane formation. While high viscosity reduces the amount of suspension leakage, the prolonged persistence of subretinal fluid due to prolonged retinal detachment may not have affected the total number of cells leaking into the vitreous. Furthermore, ERM was observed more frequently with the transplantation medium containing Provisc or Viscoat diluted 200-fold. Although the reason is unclear, leakage occurs below a certain viscosity threshold, and the presence of the leaked hyaluronic acid in the vitreous cavity may facilitate the formation of a preretinal membrane using the hyaluronic acid as a scaffold. On the other hand, when a transplantation medium containing Provisc or Viscoat diluted 100-fold was used, no ERM formation was observed. Therefore, it was found that adding Provisc or Viscoat diluted 100-fold to the medium is preferable for suppressing cell leakage.
[0106] After the observation period (4, 13, and 26 weeks after surgery), the eyeballs were enucleated, fixed, and embedded in paraffin. Ten sections (3-4 μm thick) were prepared at 0.56 mm intervals to cover the bleb. To assess engraftment, fluorescent immunostaining was performed according to standard procedures using an anti-human PMEL17 antibody (Novus Biologicals, NBP2-47780AF647, mouse; Abcam, ab137062, rabbit), a RPE cell marker, and an anti-human CD147 antibody (R&D Systems, AF972, goat) for human cells. Stained specimens were observed under a fluorescence microscope (KEYENCE, BZ-X810) or a slide scanner (Zeiss, Axio Scan.Z1), and the area containing the positive staining was imaged.
[0107] The anti-CD147 antibody used showed a strong positive signal in some areas where human iPS cell-derived RPE cells were thought to have engrafted, but the entire retinal pigment epithelium of the cynomolgus monkey was stained, suggesting that it also cross-reacts with monkey antigens. Therefore, the anti-PMEL17 antibody positive signal was used as the primary indicator of the engraftment and distribution of human iPS cell-derived RPE cells, and the anti-CD147 antibody was used in multiple staining to make it easier to distinguish the monkey retinal pigment epithelium during observation.
[0108] Furthermore, to quantitatively analyze the engraftment performance, each section corresponding to the total number of engraftment sites that continuously showed anti-PMEL17 antibody positivity (sites where positive cells were continuously observed under the retina over a distance of 100 μm or more) was evaluated using the following four-grade evaluation (Grades 0 to 3), and the results for 10 sections were summed to calculate a total score (0 to 30) for each individual. Four-grade evaluation Grade 0: No positive cells Grade 1: Minimal (no continuous engraftment was observed, but positive cells were observed) Grade 2: Moderate (one or two continuous engraftment sites were observed) Grade 3: Marked (three or more continuous engraftment sites were observed)
[0109] PMEL17-positive areas were observed in most monkeys. Furthermore, many of these positive areas were observed as a single layer within the monkey RPE cell layer, confirming that the administered human iPS cell-derived RPE cells had integrated and engrafted into the RPE layer. Representative low-magnification immunofluorescence images of the Provisc 100x dilution group (individual No. 1, 4 weeks after surgery) are shown in Figures 3 and 4. Figure 3 (A) shows an image with multiple stainings superimposed; (B) shows DAPI staining alone; Figure 4 (A) shows CD147 staining alone; and (B) shows PMEL17 staining. The arrows in Figure 3 (A) indicate areas where RPE cells continuously engrafted. Five continuous engraftment sites were confirmed in this individual (individual No. 1), rated as Grade 3. Figure 5 shows a high-magnification immunofluorescence image of individual No. 1 (4 weeks after surgery). (A) shows an image with multiple stainings superimposed; (B) to (D) show images of each staining alone.
[0110] Engraftment was scored for the hyaluronic acid-added medium (100-fold dilution) group, which showed a good inhibitory effect on cell leakage. Furthermore, because the administration volume (total number of administered cells) differed for each individual, a score per unit number of cells was calculated. The results are shown in Table 3. As can be seen from Table 3, under the conditions using Provisc, the administered cells engrafted over a wide area, whereas under the conditions using Viscoat, engraftment was observed only in a small area.
[0111] From the above, it was found that a transplant medium containing a specific concentration of sodium hyaluronate with an average molecular weight of 1.5 to 3.9 million is optimal for preventing leakage of administered cells into the vitreous cavity and achieving widespread engraftment.
[0112] Example 3: Viscosity measurement of transplantation media The following transplantation media were prepared. Based on the results of Examples 1 and 2, media (2) to (7) are suitable transplantation media, and among them, media (3) and (6), especially media (6), are preferred.
[0113] (1) Hank's balanced salt solution (HBSS(+)) (2) Viscoat diluted 20 times (HBSS(+): Viscoat = 20:1) (3) Viscoat diluted 100 times (HBSS(+): Viscoat = 100:1) (4) Viscoat diluted 200 times (HBSS(+): Viscoat = 200:1) (5) Provisc diluted 20 times (HBSS(+): Provisc = 20:1) (6) Provisc diluted 100 times (HBSS(+): Provisc = 100:1) (7) Provisc diluted 200 times (HBSS(+): Provisc = 200:1)
[0114] The viscosities of the above media (1) to (7) were measured using a viscosity measuring device under the conditions of 25°C and a shear rate of 1 / s = 2. The results are shown in Table 4.
[0115] Furthermore, the correlation between shear rate and viscosity was measured for the above media (1) to (7) at 25°C using a viscosity measuring device. The results are shown in Table 5. As a result, it was found that, among media (1) to (7), the amount of change in viscosity for media (3) and (6) was greater than for the other media.
Claims
1. A transplantation medium for transplanting retinal pigment epithelial cells under the retina, the medium having a viscosity of 1.5 to 4 mPa·s at a shear rate of 2 (1 / s) at 25°C, and comprising hyaluronic acid and a pharma- ceutical acceptable aqueous liquid.
2. 2. The implantation medium of claim 1, having a viscosity of 2 to 3 mPa·s at a shear rate of 2 (1 / s) at 25°C.
3. 3. The transplant medium according to claim 1 or 2, wherein the viscosity at a shear rate of 1000 (1 / s) at 25°C is 3 mPa·s or less, and the difference in viscosity between the viscosity at a shear rate of 1 (1 / s) and the viscosity at a shear rate of 10 (1 / s) is 0.5 to 1.5 mPa·s.
4. The implantation medium according to claim 1 or 2, having a pH of 7.0 to 7.
5.
5. 3. The implantation vehicle of claim 1 or 2, wherein the pharma- ceutically acceptable aqueous liquid is a balanced salt solution.
6. 3. The implantation medium of claim 1 or 2, which is free of antimicrobial agents and preservatives.
7. 3. The implantation medium according to claim 1 or 2, which is free of chondroitin sulfate.
8. The implantation medium according to claim 1 or 2, wherein the vitreous body is replaced with air after subretinal implantation.
9. A transplantation composition comprising retinal pigment epithelial cells for transplantation and the transplantation medium according to claim 1 or 2.
10. The retinal pigment epithelial cells for transplantation were 1×10 6 cells / mL~5×10 7 The transplant composition of claim 9 , wherein the transplant composition is present at a concentration of cells / mL.
11. The transplant composition of claim 9, wherein the volume of a single transplant is 10 μL to 100 μL.
